Ozempic is a GLP-1 receptor agonist, a class of injectable medications that mimic a natural gut hormone to lower blood sugar. Its active ingredient is semaglutide, a lab-modified version of a hormone your body already produces called GLP-1 (glucagon-like peptide-1). The FDA approved Ozempic in 2017 specifically for adults with type 2 diabetes, not as a general weight loss drug.
How GLP-1 Receptor Agonists Work
After you eat, your gut releases GLP-1 to signal your pancreas to produce insulin. The natural hormone breaks down in minutes. Semaglutide is engineered to last much longer in the body, which is why Ozempic only needs to be injected once a week rather than multiple times a day.
The drug works through several mechanisms at once. It stimulates insulin release when blood sugar is high, slows the rate at which your stomach empties food into the intestines, and reduces the amount of sugar your liver releases into the bloodstream. It also acts on appetite-regulating pathways in the brain, which is why people taking it often feel less hungry. That appetite suppression is a side effect of the diabetes drug, not its primary purpose.
What Ozempic Is Approved to Treat
Ozempic has three FDA-approved uses, all in adults with type 2 diabetes:
- Blood sugar control: As an add-on to diet and exercise to improve blood sugar levels.
- Cardiovascular protection: To reduce the risk of heart attack, stroke, or cardiovascular death in people who also have established heart disease.
- Kidney protection: To slow kidney decline and reduce the risk of end-stage kidney disease in people who also have chronic kidney disease.
The cardiovascular benefit is well documented. In a major clinical trial called SUSTAIN-6, patients taking semaglutide had a 26% lower rate of major cardiovascular events compared to placebo. The risk of nonfatal stroke dropped by 39%.
How Ozempic Differs From Wegovy
Wegovy contains the exact same active ingredient, semaglutide, but is prescribed under a different name at different doses for a different condition. Ozempic is approved for type 2 diabetes with a maximum dose of 2 mg per week. Wegovy is approved for weight management in people with obesity or who are overweight with at least one weight-related health condition, and its maximum dose is 2.4 mg per week.
As one endocrinologist at UCHealth put it, “The drug product itself is the same. They are just prescribed under different names with slightly different doses and different indications.” Ozempic is not FDA-approved for weight loss, even though many people experience weight loss while taking it.
How It’s Taken
Ozempic is a once-weekly injection given just under the skin in the abdomen, thigh, or upper arm. You pick a day of the week and stick with it, injecting at any time of day, with or without food. The pen is prefilled, so there’s no mixing or measuring involved.
Treatment starts with a low dose of 0.25 mg for the first four weeks. This starting dose isn’t meant to be therapeutic. It’s designed to let your body adjust before the dose increases. After that initial month, the dose moves to 0.5 mg, then potentially up to 1 mg or 2 mg depending on how well your blood sugar responds and how you tolerate the medication. Each step typically lasts at least four weeks before the next increase.
Common Side Effects
Because GLP-1 receptor agonists slow stomach emptying and affect appetite signaling, digestive side effects are the most common issue. In clinical trials, about 20% of patients on the 1 mg dose experienced nausea, compared to 6% on placebo. Diarrhea affected roughly 9% of patients, and vomiting occurred in about 9% as well. Abdominal pain and constipation were also reported in more than 5% of patients.
These side effects are most likely during dose increases and tend to improve over time. The gradual titration schedule exists specifically to minimize them. Eating smaller meals and avoiding high-fat foods can also help.
What Makes Semaglutide Different From Older Diabetes Drugs
Older diabetes medications like sulfonylureas force the pancreas to release insulin regardless of blood sugar levels, which can cause dangerous drops in blood sugar (hypoglycemia). Semaglutide is glucose-dependent, meaning it primarily stimulates insulin when blood sugar is already elevated. This makes severe low blood sugar uncommon when semaglutide is used on its own.
Unlike insulin, which patients may need to inject before every meal, Ozempic’s once-weekly schedule is considerably simpler. And unlike metformin, the most commonly prescribed first-line diabetes drug taken as a daily pill, Ozempic has demonstrated direct cardiovascular and kidney protective benefits in clinical trials. These properties have made GLP-1 receptor agonists one of the most significant advances in type 2 diabetes treatment in recent years, often prescribed alongside metformin when blood sugar isn’t well controlled with one medication alone.